GlassScriptPhysician profile
Ian A Bellard
NPI 1255955779
$6,023.34
in general payments reported to CMS, 2019-2025
15 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,321 · 2022: $1,008 · 2023: $646 · 2024: $860 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,684.22 | 2022-2025 | Infuse, Miebo |
| Alcon Vision LLC | $1,351.30 | 2021-2025 | Total30, Precision7, Precision 1 |
| Coopervision INC. | $1,006.06 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $942.45 | 2021-2025 | Acuvue |
| Glaukos Corporation | $238.88 | 2021-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.38 | 2021 | |
| Oyster Point Pharma, INC. | $119.17 | 2022 | |
| Allergan, INC. | $116.60 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $114.27 | 2021 | |
| Optos, INC. | $109.23 | 2021 | |
| Dompe US, INC. | $50.06 | 2024 | Oxervate |
| Lkc Technologies, INC. | $33.81 | 2024 | |
| Sight Sciences, INC. | $24.79 | 2022 | |
| Abbvie INC. | $22.12 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Bellard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.